Table 1.
Association between baseline characteristics and CRRP (univariate analyses)*.
Fig 1.
Patient enrollment flow chart and the therapeutic course during the 1-year observation after the baseline in our RA cohort.
HDA: high disease activity; MDA: moderate disease activity; LDA: low disease activity; csDMARDs: conventional synthetic disease-modifying antirheumatic drugs; bDMARDs: biological disease-modifying antirheumatic drugs.
Fig 2.
Cumulative probability plots of actual radiographic progression assessed by mTSS (U/year) in the cohort (n = 198).
mTSS: modified total Sharp score.
Fig 3.
Cumulative probability plots of changes in mTSS for 1 year in the ACPA-positive patients versus the ACPA-negative patients.
ACPA: anti-citrullinated peptide antibodies; mTSS: modified total Sharp score.
Table 2.
Prediction of CRRP in multiple logistic regression analysis*.
Table 3.
Prediction of CRRP in multiple logistic regression analysis (continuous variables)*.
Table 4.
Prediction of CRRP in multiple logistic regression analysis (binary variables)*.
Table 5.
Patients’ characteristics with disease activity (univariate analyses)*.